See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Autolus Therapeutics PLC Sponsored ADR (AUTL) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Autolus Therapeutics PLC Sponsored ADR (AUTL) - free report >>
Image: Bigstock
Autolus Therapeutics PLC Sponsored ADR (AUTL) Moves 35.5% Higher: Will This Strength Last?
Autolus Therapeutics PLC Sponsored ADR (AUTL - Free Report) shares soared 35.5% in the last trading session to close at $6.76. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 10.1% loss over the past four weeks.
The company announced that its investigational CD19 CAR T cell therapy, AUTO1, achieved 100% complete remission in patients with relapsed/refractory indolent non-Hodgkin lymphoma in an early-stage study. This might have been driving the rally.
Price and Consensus
This company is expected to post quarterly loss of $0.52 per share in its upcoming report, which represents a year-over-year change of +16.1%. Revenues are expected to be $0.31 million, up 7.9% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Autolus Therapeutics PLC Sponsored ADR, the consensus EPS estimate for the quarter has been revised 2.3% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on AUTL going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank 3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>